{"id":696,"date":"2024-02-29T09:58:00","date_gmt":"2024-02-29T08:58:00","guid":{"rendered":"https:\/\/temporary.nolato.com\/mfn_news\/nolato-reports-comparative-figures-for-its-new-group-structure\/"},"modified":"2024-02-29T09:58:00","modified_gmt":"2024-02-29T08:58:00","slug":"nolato-reports-comparative-figures-for-its-new-group-structure","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/fr\/mfn_news\/nolato-reports-comparative-figures-for-its-new-group-structure\/","title":{"rendered":"Nolato reports comparative figures for its new group structure"},"content":{"rendered":"
\n

As previously announced, from the first quarter of 2024 Nolato will conduct the Group\u2019s operations via two business areas \u2013 Medical Solutions and Engineered Solutions. The new Engineered Solutions business area includes the former Industrial, Consumer Electronics and EMC areas.<\/p>\n

Below both quarterly and full-year figures for 2022 and 2023 based on the new group structure are presented. The report for the first quarter of 2024 will be published on May 6.<\/p>\n

Sales and margin by segment<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Net sales <\/strong>(SEKm)<\/td>\n<\/td>\nQ1<\/strong><\/td>\nQ2<\/strong><\/td>\nQ3<\/strong><\/td>\nQ4<\/strong><\/td>\nFull year<\/strong><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Medical Solutions<\/td>\n2023<\/td>\n1,324<\/td>\n1,364<\/td>\n1,320<\/td>\n1,300<\/td>\n5,308<\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n1,088<\/td>\n1,214<\/td>\n1,245<\/td>\n1,312<\/td>\n4,859<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Engineered Solutions<\/td>\n2023<\/td>\n1,153<\/td>\n1,114<\/td>\n1,020<\/td>\n958<\/td>\n4,245<\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n1,792<\/td>\n1,693<\/td>\n1,382<\/td>\n1,055<\/td>\n5,922<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Intra-Group adj., Parent Co<\/td>\n2023<\/td>\n-1<\/td>\n\u2013<\/td>\n\u2013<\/td>\n-6<\/td>\n-7<\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n-1<\/td>\n-2<\/td>\n-1<\/td>\n-3<\/td>\n-7<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Group total<\/td>\n2023<\/td>\n2,476<\/td>\n2,478<\/td>\n2,340<\/td>\n2,252<\/td>\n9,546<\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n2,879<\/td>\n2,905<\/td>\n2,626<\/td>\n2,364<\/td>\n10,774<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Operating profit <\/strong>(EBITA) (SEKm)<\/td>\n<\/td>\nQ1<\/strong><\/td>\nQ2<\/strong><\/td>\nQ3<\/strong><\/td>\nQ4<\/strong><\/td>\nFull year<\/strong><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Medical Solutions<\/td>\n2023<\/td>\n132<\/td>\n138<\/td>\n126<\/td>\n129<\/td>\n525<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n10.0<\/em><\/td>\n10.1<\/em><\/td>\n9.5<\/em><\/td>\n9.9<\/em><\/td>\n9.9<\/em><\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n106<\/td>\n121<\/td>\n104<\/td>\n126<\/td>\n457<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n9.7<\/em><\/td>\n10.0<\/em><\/td>\n8.4<\/em><\/td>\n9.6<\/em><\/td>\n9.4<\/em><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Engineered Solutions<\/td>\n2023<\/td>\n68<\/td>\n72<\/td>\n74<\/td>\n52<\/td>\n266<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n5.9<\/em><\/td>\n6.5<\/em><\/td>\n7.3<\/em><\/td>\n5.4<\/em><\/td>\n6.3<\/em><\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n163<\/td>\n146<\/td>\n110<\/td>\n43<\/td>\n462<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n9.1<\/em><\/td>\n8.6<\/em><\/td>\n8.0<\/em><\/td>\n4.1<\/em><\/td>\n7.8<\/em><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Intra-Group adj., Parent Co<\/td>\n2023<\/td>\n-7<\/td>\n-12<\/td>\n-67<\/td>\n-4<\/td>\n-90<\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n-2<\/td>\n-3<\/td>\n\u2013<\/td>\n-6<\/td>\n-11<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Group total<\/td>\n2023<\/td>\n193<\/td>\n198<\/td>\n133<\/td>\n177<\/td>\n701<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n7.8<\/em><\/td>\n8.0<\/em><\/td>\n5.7<\/em><\/td>\n7.9<\/em><\/td>\n7.3<\/em><\/td>\n<\/tr>\n
<\/td>\n2022<\/td>\n267<\/td>\n264<\/td>\n214<\/td>\n163<\/td>\n908<\/td>\n<\/tr>\n
EBITA-margin, %<\/em><\/td>\n<\/td>\n9.3<\/em><\/td>\n9.1<\/em><\/td>\n8.1<\/em><\/td>\n6.9<\/em><\/td>\n8.4<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Contact<\/strong><\/p>\n

\n

Per-Ola Holmstr\u00f6m, CFO, +46 (0)705 763340, per-ola.holmstrom@nolato.com<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n

\n

Nolato is a Swedish group with operations in Europe, Asia, and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors. Nolato\u2019s shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. \u00a0<\/em>www.nolato.com\/IR<\/a><\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

Nolato reports comparative figures for its new group structure<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

As previously announced, from the first quarter of 2024 Nolato will conduct the Group\u2019s operations via two business areas \u2013 Medical Solutions and Engineered Solutions. The new Engineered Solutions business area includes the former Industrial, Consumer Electronics and EMC areas. Below both quarterly and full-year figures for 2022 and 2023 based on the new group… Continue reading Nolato reports comparative figures for its new group structure<\/span><\/a><\/p>\n","protected":false},"template":"","class_list":["post-696","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"fr","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/mfn_news\/696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/fr\/wp-json\/wp\/v2\/media?parent=696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}